Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

On October 11, 2022 Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, reported the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity (Press release, Accutar Biotechnology, OCT 11, 2022, View Source [SID1234621915]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initiation of this study marks the first program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0682 Phase 1 study in the US late last year and the IND clearance by the China National Medical Products Administration (NMPA) earlier this year," said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. "Breast cancer is the most common cancer type among Chinese women. We look forward to accelerating the development of AC0682 globally with the goal of bringing transformative medicines to patients worldwide."

The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in Chinese patients with ER-positive breast cancer. Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05489679).

About AC0682

AC0682 is an investigational orally bioavailable, chimeric degrader of ERα for the potential treatment of ER-positive breast cancers. ERα is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ERα. In preclinical studies, AC0682 demonstrated potent and selective ERα protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models.

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

On October 11, 2022 AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, reported favorable data on the combined use of two state-of-the-art assays to evaluate the genotoxicity risk of integrating vectors used in hematopoietic stem cell (HSC) gene therapy prior to clinical use, at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland (Press release, AVROBIO, OCT 11, 2022, View Source [SID1234621914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In collaboration with Professor Axel Schambach, Ph.D., Institute of Experimental Hematology, Hannover Medical School, Germany, AVROBIO is pioneering the use of two advanced preclinical cell-based assays — in vitro immortalization (IVIM) assay and the novel surrogate assay for genotoxicity assessment (SAGA) — to evaluate viral vectors before they move into clinical programs. Together these assays are designed to assess which vectors are less likely to exhibit genotoxic behavior and monitor if these vectors activate proto-oncogenes (genes that may lead to cancer).

"Our work provides insight into the early molecular events of genotoxicity following HSC transduction with integrating vectors and presents a powerful machine-learning approach to prospectively estimate the genotoxicity risk of integrating vectors for gene therapy," said Professor Schambach, also associated with the Division of Hematology/Oncology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, whose work includes data on more than 30 commonly used vectors. "These assays enable preclinical risk assessment of gene therapy vectors, potentially paving the way for safer gene therapy vectors used in clinical trials."

AVROBIO uses these assays to inform vector selection during preclinical development. In addition, to date, AVROBIO has seen no cases of insertional oncogenesis in any of its clinical programs.

"Safety is at the forefront of our work at AVROBIO and incorporated in the development of our plato platform, which includes our advanced vector design, optimized for safety as well as transgene expression and protein uptake," said AVROBIO President and CEO Geoff MacKay. "Combining these assays helps assess vector genotoxicity risk early in preclinical development and further reaffirms that not all lentiviral vectors are designed the same."

IVIM/SAGA as screening tools during lentiviral vector selection

In its research, AVROBIO used the two assays in combination to determine the potential genotoxicity risk of six lentiviral vectors. Five of the vectors used the EF1 α short promoter (EFS), while the sixth vector used the modified enhancer/promoter of the murine myeloproliferative sarcoma virus, or MND, promoter. Vectors were compared to a non-transduced mock control and a positive genotoxic control, the non-SIN gamma-retroviral vector (RSF91).

The in vitro immortalization (IVIM) assay quantifies the risk of vector-induced cellular transformation. The technique assesses genotoxicity by determining how likely a vector is to insert near and activate proto-oncogenes, such as MECOM, and lead to an over-proliferation of cells. In this study, to quantify the risk of vector-induced cellular transformation, mouse hematopoietic stem and progenitor cell (HSPC) proliferation was monitored after transduction. IVIM determined that the five EFS vectors drove cell growth in a manner indistinguishable from non-transduced cells. The vector using the MND promoter, however, exhibited cell growth that was statistically significantly different from non-transduced cells and similar to the positive genotoxic control.

The second and newer assay assesses genotoxicity more directly. The novel surrogate assay for genotoxicity assessment (SAGA) relies on the observation that genotoxic vectors induce a unique gene expression signature that is linked to stemness and oncogenesis in mouse HSPCs. Machine learning algorithms developed from transcriptional data of known genotoxic vectors are used to estimate the transformational potential of candidate vectors. The SAGA assay can evaluate vectors with known genotoxic potential with an accuracy of 90.9%. In this study, SAGA data showed that the five vectors with EFS promoters were statistically distinct from the genotoxic positive control and therefore displayed lower genotoxic risk, whereas four of nine (44%) samples from cells transduced with a lentiviral vector containing an MND internal promoter had gene enrichment scores associated with insertional oncogenesis.

These findings enable the estimation of clinically translatable insertional oncogenesis risk of integrating vectors during preclinical development. AVROBIO uses the EFS promoter in its clinical programs.

The Hannover Medical School team working with Professor Schambach and Michael Rothe, Ph.D., has previously published their data in Molecular Therapy.

Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting

On October 11, 2022 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting taking place in Boston from November 8-12, 2022 (Press release, Palleon Pharmaceuticals, OCT 11, 2022, View Source [SID1234621913]). E-602 Bi-Sialidase is a first-in-class, glyco-immune checkpoint inhibitor which restores anti-tumor immunity by enzymatically degrading immunosuppressive sialoglycans in hypersialylated tumors and immune cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Trials-in-Progress poster will include the specifics of the GLIMMER-01 trial (NCT#05259696) which is designed to assess the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602. The first patient was dosed in March of this year.

Details of the poster presentation are as follows:

Presentation Type: Poster Presentation (Abstract: #772)
Title: A Phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
Session: Poster Hall Session
Timing: November 11, 2022, 9:00 a.m. – 8:30 p.m. EST
Location: Hall C

The poster will appear on Palleon Pharmaceuticals’ website following the presentation.

TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer

On October 11, 2022 TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, reported that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication (Press release, TILT Biotherapeutics, OCT 11, 2022, View Source [SID1234621911]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s (a tradename of Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is for platinum resistant or refractory ovarian cancer (PROTA, also called TILT-T563). The US patient, treated at the Mayo Clinic, should complete enrollment in the first cohort of three patients, the other two located in Finland. The Phase I trial is expected to enroll up to 15 patients.

The company’s European and US open phase I clinical programs now cover several cancer types including ovarian cancer, head and neck cancer, and melanoma. In September, the company announced a new collaboration and supply agreement with MSD to evaluate TILT-123 in combination with KEYTRUDA in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.

TILT Biotherapeutics’ CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with earlier versions of oncolytic viruses, said, "Ovarian cancer is a killer disease with a pressing need for better therapies. There are no oncolytic viruses or check point inhibitors approved for use in that indication. The first US patient dosed is a significant milestone as we strive to make a difference using our armed oncolytic viruses in this difficult to treat disease. It’s a pleasure to work with the prestigious Mayo Clinic to deliver such innovation with impact. We are investing in our own US operations and opening US trial sites by the end of the year, as we advance towards Phase 2 trials."

The heart of TILT’s innovative approach revolves around the use of cancer cell specific oncolytic adenoviruses, armed with cytokines and other molecules to boost the patient’s T-cell immune response to better enable it to find and destroy cancer cells.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ONI and the University of Pennsylvania Start Research Collaboration to Identify Unique Biomarkers and Characteristics to Guide Next Generation CAR-T Development

On October 11, 2022 ONI, a single-molecule imaging platform biotech, reported a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials (Press release, ONI, OCT 11, 2022, View Source [SID1234621910]). The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes. ONI’s flagship product, the Nanoimager, will allow these researchers to visualize living cells and track how single molecules interact. With a resolution down to 20 nanometres (a 10-fold improvement vs traditional microscopy), the presence and distribution of these biomarkers on CAR-T and tumor cells from patient samples can also be quantified.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The University of Pennsylvania, which includes the Center for Cellular Immunotherapies and the Abramson Cancer Center (ACC), is one of the world’s leading centers in CAR-T research, having developed the first CAR-T therapy approved by the FDA. At the ACC, Marco Ruella, MD, leads a team that focuses on the study of the mechanisms of resistance to CAR-T therapy and the development of next-generation CAR-T treatments.

"This important collaboration with the University of Pennsylvania and Dr. Ruella using our Nanoimager technology will leverage super-resolution imaging to help guide development of better CAR-T therapies and hopefully positively impact patients’ lives in the future," said Bo Jing, CEO of ONI. "The precise data obtained from viewing living cells as they interact and the light it sheds on disease mechanisms allow enormous strides to be made in the design of novel therapeutics and diagnostics."

"Despite great progress, following CAR-T treatment, a subset of patients do not respond or eventually suffer relapses. Subsequently, there is significant interest in further understanding the key factors associated with outcome and toxicity after CAR-T therapy and how these observations could help guide next-generation CAR-T therapies," Dr. Ruella said. "The use of next-generation imaging technologies that can visualize the interaction between CAR-T and tumor cells could provide key insights into mechanisms of action not available with other technologies."